GlassScriptPhysician profile
David W Hall
NPI 1558573709
$2,039.33
in general payments reported to CMS, 2019-2025
26 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $126 · 2021: $131 · 2022: $412 · 2023: $417 · 2024: $499 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $726.46 | 2020-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $183.28 | 2020-2025 | Xtandi |
| Endo Pharmaceuticals INC. | $138.32 | 2019-2020 | |
| Boston Scientific Corporation | $133.63 | 2019-2025 | Axonics, Ams 700 |
| Pfizer INC. | $123.18 | 2019-2024 | |
| Janssen Biotech, INC. | $94.15 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $82.70 | 2024-2025 | Bard Urinary Drainage Bag |
| Abbvie INC. | $73.27 | 2021-2025 | |
| Accord Healthcare, INC. | $50.37 | 2023-2024 | |
| Acerus Pharmaceuticals Corporation | $36.75 | 2022 | |
| Coloplast Corp | $36.14 | 2022 | |
| Ferring Pharmaceuticals INC. | $35.20 | 2023-2025 | Rebyota, Adstiladrin |
| Rochester Medical Corporation | $32.54 | 2020 | |
| Telix Pharmaceuticals | $30.69 | 2024 | Illuccix |
| Procept Biorobotics Corporation | $29.91 | 2024 | Aquabeam System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $28.18 | 2024 | Itind System |
| Medtronic, INC. | $26.47 | 2023 | Verify, Interstim |
| Antares Pharma, INC. | $26.09 | 2021-2022 | |
| Neotract INC. | $25.00 | 2019 | |
| Urogen Pharma, INC. | $25.00 | 2023 | Jelmyto |
| Healthtronics Stone Solutions, LLC | $20.66 | 2022 | |
| Medline Industries LP | $20.08 | 2022 | |
| 180 Medical, INC. | $17.73 | 2024 | |
| Endo USA, INC. | $17.06 | 2025 | Aveed, Xiaflex |
| Myovant Sciences INC. | $15.11 | 2022 | |
| Allergan, INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.